Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

July 31, 2008

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

Pegylated Alfa Interferon

Each patient will receive PEG-Intron administered subcutaneously one day per week of each 6 week cycle. The dose of PEG-Intron is determined based on the patient's weight and the dose level.

DRUG

sunitinib

Patients will receive sunitinib orally as a single daily dose on Days 1-28 of each 42-day cycle. The dose will depend on the dose level.

DRUG

erlotinib

Tarceva will be administered orally, 1-42 of each 42 day cycle. Dose will depend on dose level. Supplied as 150-mg, 100-mg and 25-mg strengths, white film-coated tablets for administration.

Trial Locations (1)

77030

Baylor College of Medicine - Methodist Hospital, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Schering-Plough

INDUSTRY

lead

The Methodist Hospital Research Institute

OTHER

NCT00522249 - Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC | Biotech Hunter | Biotech Hunter